Review Note
Last Update: 02/28/2024 08:31 PM
Current Deck: Step 2::Mehlman::Mehlman HY 4
PublishedCurrently Published Content
Text
54F + treated with anti-platelet agent that prevents platelets from interacting with fibrinogen; what's the agent?
{{c1::abciximab}}
Extra
monoclonal antibody against glycoproteins IIb/IIIa on platelets;
these glycoproteins carry out aggregation and are normally bridged by fibrinogen; abciximab is a fibrinogen anlogue; don't conguse aggregation (platelets to each other) via GpIIb/IIIa with adhesion (platelets to endothelium) mediated by Gp Ib.
Eptifibitide and tirofiban are lower yield drugs that also inhibit GpIIb/IIIa; abciximab is HY agent with this MOA;
HY drugs that inhibit ABP2Y12 receptor on platelets are clopidogrel and parsugrel; ticagrelor and ticlopidine are lower yield drugs that antagonize ADP2Y12
Lecture Notes
Missed Questions
Pathoma
Boards and Beyond
First Aid
Sketchy
Physeo
Additional Resources
Current Tags:
Pending Suggestions
No pending suggestions for this note.